350 related articles for article (PubMed ID: 18258852)
1. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.
Terwel D; Muyllaert D; Dewachter I; Borghgraef P; Croes S; Devijver H; Van Leuven F
Am J Pathol; 2008 Mar; 172(3):786-98. PubMed ID: 18258852
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology.
Muyllaert D; Terwel D; Borghgraef P; Devijver H; Dewachter I; Van Leuven F
Rev Neurol (Paris); 2006 Oct; 162(10):903-7. PubMed ID: 17028556
[TBL] [Abstract][Full Text] [Related]
3. Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy.
Maurin H; Chong SA; Kraev I; Davies H; Kremer A; Seymour CM; Lechat B; Jaworski T; Borghgraef P; Devijver H; Callewaert G; Stewart MG; Van Leuven F
PLoS One; 2014; 9(2):e87605. PubMed ID: 24498342
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.
Crespo-Biel N; Theunis C; Borghgraef P; Lechat B; Devijver H; Maurin H; Van Leuven F
Neurobiol Dis; 2014 Jul; 67():119-32. PubMed ID: 24704314
[TBL] [Abstract][Full Text] [Related]
5. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
6. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
7. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.
Stancu IC; Ris L; Vasconcelos B; Marinangeli C; Goeminne L; Laporte V; Haylani LE; Couturier J; Schakman O; Gailly P; Pierrot N; Kienlen-Campard P; Octave JN; Dewachter I
FASEB J; 2014 Jun; 28(6):2620-31. PubMed ID: 24604080
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model.
Jimenez S; Torres M; Vizuete M; Sanchez-Varo R; Sanchez-Mejias E; Trujillo-Estrada L; Carmona-Cuenca I; Caballero C; Ruano D; Gutierrez A; Vitorica J
J Biol Chem; 2011 May; 286(21):18414-25. PubMed ID: 21460223
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F
Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370
[TBL] [Abstract][Full Text] [Related]
10. Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β.
Maurin H; Lechat B; Borghgraef P; Devijver H; Jaworski T; Van Leuven F
Eur J Neurosci; 2014 Jul; 40(2):2442-53. PubMed ID: 24754737
[TBL] [Abstract][Full Text] [Related]
11. Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study.
Chong SA; Benilova I; Shaban H; De Strooper B; Devijver H; Moechars D; Eberle W; Bartic C; Van Leuven F; Callewaert G
Neurobiol Dis; 2011 Dec; 44(3):284-91. PubMed ID: 21807097
[TBL] [Abstract][Full Text] [Related]
12. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
13. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
14. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.
Köhler C; Dinekov M; Götz J
Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633
[TBL] [Abstract][Full Text] [Related]
15. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis.
Terron HM; Parikh SJ; Abdul-Hay SO; Sahara T; Kang D; Dickson DW; Saftig P; LaFerla FM; Lane S; Leissring MA
Alzheimers Res Ther; 2024 Apr; 16(1):70. PubMed ID: 38575959
[TBL] [Abstract][Full Text] [Related]
16. Curcumin Decreases Hyperphosphorylation of Tau by Down-Regulating Caveolin-1/GSK-3β in N2a/APP695swe Cells and APP/PS1 Double Transgenic Alzheimer's Disease Mice.
Sun J; Zhang X; Wang C; Teng Z; Li Y
Am J Chin Med; 2017; 45(8):1667-1682. PubMed ID: 29132216
[TBL] [Abstract][Full Text] [Related]
17. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.
Haggerty T; Credle J; Rodriguez O; Wills J; Oaks AW; Masliah E; Sidhu A
Eur J Neurosci; 2011 May; 33(9):1598-610. PubMed ID: 21453448
[TBL] [Abstract][Full Text] [Related]
19. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice.
Bolmont T; Clavaguera F; Meyer-Luehmann M; Herzig MC; Radde R; Staufenbiel M; Lewis J; Hutton M; Tolnay M; Jucker M
Am J Pathol; 2007 Dec; 171(6):2012-20. PubMed ID: 18055549
[TBL] [Abstract][Full Text] [Related]
20. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
